We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Zinc Isotope Test Helps Detect Early Breast Cancer

By LabMedica International staff writers
Posted on 23 Dec 2014
It may be possible to detect the early signs of breast cancer with a test that measures changes in zinc isotopes as measurable changes in zinc isotope composition can be detected in breast tissue and could be used as a biomarker for early breast cancer.

Breast cancers that are found after they start to cause symptoms, for example, a new lump or swelling, or changes in nipple shape and texture, are usually larger and more likely to have started spreading than breast cancers found before symptoms emerge. More...
The size of a breast tumor and how far it has spread are two of the most important factors in predicting the success of treatment and the longer-term outlook for the patient.

Scientists at the University of Oxford (UK) determined the zinc concentrations and isotopic composition of blood and blood serum of healthy controls and breast cancer patients, alongside a suite of 10 breast tissues, predominantly obtained from breast cancer patients. They applied techniques normally used by earth scientists to understand climate change and the birth of planets, to study how the body processes metals.

The techniques which are over 100 times more sensitive to changes in metal composition than any clinical laboratory instruments, measure the levels of trace metals in terms of the relative proportions of their different isotopic forms.

Zinc and copper concentrations were determined by multiple collector inductively coupled plasma mass spectrometry (MC-ICP-MS) and inductively coupled plasma atomic emission spectroscopy (ICP-AES). Isotope analyses were performed using the Nu Instruments Nu Plasma HR MC-ICP-MS at the appropriate resolution mode (Copper: low, Zinc: medium) with either an Aridus (Cetac; Omaha, NE, USA) or a desolvating sample system (DSN) (Nu Instruments, Oxford, UK). The reproducibility of the methods was monitored by repeat measurements of an in house standard alongside sample.

The investigators found that the breast cancer tumors had a significantly lighter zinc isotopic composition than the blood, serum and healthy breast tissue of both the breast cancer patients and the healthy controls. The team suggests the subtle differences in zinc composition occur because tumor cells process the metal differently to normal cells. They also found similar changes in copper in one of the breast cancer patients.

Fiona Larner, PhD, the lead author of the study, said, “We have known for over 10 years that breast cancer tissue carries high levels of zinc, but the underlying processes that cause this are not well understood. Our study shows that techniques commonly used in earth sciences can help us to understand not only how zinc is used by tumor cells but also how breast cancer can lead to changes in zinc in an individual's blood. Further research is already under way to see what changes in other metals may be caused by other cancers.” The study was published on December 1, 2014, in the journal Metallomics.

Related Links:

University of Oxford 
Cetac 
Nu Instruments  



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.